ArticleCancer medicine2024

Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.

Thierry Petit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.